Yoon Kyung Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoon Kyung Cho has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Hyun Mi Kang
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
7 shared publications - Dae Chul Jeong
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea
3 shared publications - Jin Han Kang
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Kyu Ri Kang
The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Ye Ji Kim
Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea
3 shared publications - Bin Ahn
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
Real-World Serologic Responses and Recorded Medically Attended Events After the Live Attenuated MAV/06-Strain Varicella Vaccine in Adolescents and Adults: A Retrospective Cohort Study
Background: Evidence on the real-world use of the MAV/06-strain live attenuated varicella vaccine (BARYCELA inj.) in adolescents and adults is limited. We described postvaccination ELISA seropositivity and recorded medically attended events in recipients aged ≥ 13 years. Methods: This retrospective cohort study included recipients vaccinated at a tertiary academic medical center in South Korea. Serologic analyses included selected participants documented as VZV IgG-negative at baseline who subsequently underwent postvaccination testing during routine care; dose scheduling and testing were individualized according to prior vaccination documentation and clinical need. Hospital encounters within 42 days after vaccination and institution-associated reports in the national adverse-event reporting system were reviewed. Results: Of 1715 administered doses, 988 patients aged ≥ 13 years received 1295 doses and comprised the safety cohort. The serology cohort included 199 participants and 202 dose-specific assessments. ELISA seropositivity was observed in 80/98 participants (81.6%; 95% CI, 72.8–88.1%) in the post-dose 1 cohort and 90/104 (86.5%; 95% CI, 78.7–91.8%) in the post-dose 2 cohort. Nine medically attended events were identified within 42 days (0.69% per administered dose; 95% CI, 0.32–1.32%), of which one mild fever episode was considered possibly related to vaccination. Substantial postvaccination ELISA seropositivity was observed in this selected cohort of adolescents and adults. Few medically attended events were identified in the available institutional records and national adverse-event reports, and one mild fever episode was considered possibly related to vaccination. Prospective studies with paired, protocol-timed sampling and cellular immune assessments are needed.
Open AccessReal-World Serologic Responses and Recorded Medically Attended Events After the Live Attenuated MAV/06-Strain Varicella Vaccine in Adolescents and Adults: A Retrospective Cohort Study
Background: Evidence on the real-world use of the MAV/06-strain live attenuated varicella vaccine (BARYCELA inj.) in adolescents and adults is limited. We described postvaccination ELISA seropositivity and recorded medically attended events in recipients aged ≥ 13 years. Methods: This retrospective cohort study included recipients vaccinated at a tertiary academic medical center in South Korea. Serologic analyses included selected participants documented as VZV IgG-negative at baseline who subsequently underwent postvaccination testing during routine care; dose scheduling and testing were individualized according to prior vaccination documentation and clinical need. Hospital encounters within 42 days after vaccination and institution-associated reports in the national adverse-event reporting system were reviewed. Results: Of 1715 administered doses, 988 patients aged ≥ 13 years received 1295 doses and comprised the safety cohort. The serology cohort included 199 participants and 202 dose-specific assessments. ELISA seropositivity was observed in 80/98 participants (81.6%; 95% CI, 72.8–88.1%) in the post-dose 1 cohort and 90/104 (86.5%; 95% CI, 78.7–91.8%) in the post-dose 2 cohort. Nine medically attended events were identified within 42 days (0.69% per administered dose; 95% CI, 0.32–1.32%), of which one mild fever episode was considered possibly related to vaccination. Substantial postvaccination ELISA seropositivity was observed in this selected cohort of adolescents and adults. Few medically attended events were identified in the available institutional records and national adverse-event reports, and one mild fever episode was considered possibly related to vaccination. Prospective studies with paired, protocol-timed sampling and cellular immune assessments are needed.
- Open Access
- 30 June 2026
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 4 (1)
Similarities and Differences between Systemic Juvenile Idiopathic Arthritis and Kawasaki Disease
Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease characterized by fever, rash, and arthritis. In actual practice, SJIA is sometimes confused with Kawasaki disease (KD), as they share clinical and laboratory findings. Compared to those with KD, patients with SJIA present with more frequent joint symptoms and organ dysfunction and have more severe overall laboratory findings. However, it is important to note that clinical and laboratory findings of SJIA can also occur in severe forms of KD. Hyperferritinemia and elevated interleukin (IL)-18 levels are highly specific for SJIA and can serve as useful biomarkers for differentiating SJIA from KD. The most significant difference between SJIA and KD is the chronic nature of the disease course. Therefore, the possibility of overlooked SJIA should be considered in patients with KD who present with recurrent fever, rash, or arthritis. Approximately 0.5% of patients with KD are ultimately diagnosed with SJIA. Although the relationship between SJIA and KD is still partially understood, it will be an interesting and important research topic for KD-like hyperinflammatory diseases, including SJIA and KD.
- 30 June 2026
- Published by Korean Society of Kawasaki Disease in Kawasaki Disease
- Vol. 4 (1)
Open AccessSimilarities and Differences between Systemic Juvenile Idiopathic Arthritis and Kawasaki Disease
Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease characterized by fever, rash, and arthritis. In actual practice, SJIA is sometimes confused with Kawasaki disease (KD), as they share clinical and laboratory findings. Compared to those with KD, patients with SJIA present with more frequent joint symptoms and organ dysfunction and have more severe overall laboratory findings. However, it is important to note that clinical and laboratory findings of SJIA can also occur in severe forms of KD. Hyperferritinemia and elevated interleukin (IL)-18 levels are highly specific for SJIA and can serve as useful biomarkers for differentiating SJIA from KD. The most significant difference between SJIA and KD is the chronic nature of the disease course. Therefore, the possibility of overlooked SJIA should be considered in patients with KD who present with recurrent fever, rash, or arthritis. Approximately 0.5% of patients with KD are ultimately diagnosed with SJIA. Although the relationship between SJIA and KD is still partially understood, it will be an interesting and important research topic for KD-like hyperinflammatory diseases, including SJIA and KD.
- Open Access
Early Gut Microbiome–Short-Chain Fatty Acid Axis Disruption May Be Associated with Delayed Recovery in Critically Ill Children
Background: The gut microbiome contributes to immune–metabolic homeostasis through microbial-derived metabolites such as short-chain fatty acids (SCFAs). However, whether early disruption of the gut microbiome–SCFA axis identifies impaired clinical recovery in pediatric intensive care unit (PICU) patients remains unclear. Biological markers reflecting the recovery trajectory beyond conventional severity scores remain poorly characterized in pediatric critical illness. We therefore investigated whether early microbiome disruption and fecal SCFA profiles are associated with recovery trajectory in critically ill children. Methods: In this prospective observational study (N = 26), fecal samples were collected within 5 days of PICU admission. Microbial diversity was assessed using 16S rRNA gene sequencing (Shannon index), and fecal SCFAs were quantified using targeted metabolomics. Disease severity was assessed using the Pediatric Index of Mortality 3 (PIM3). The primary outcome was PICU length of stay (LOS) as a pragmatic indicator of metabolic and functional recovery trajectory in critically ill children. Results: Younger age and higher disease severity showed a trend toward reduced microbial diversity (β = 0.066, p = 0.089, and β = −0.054, p = 0.089). Early loss of gut microbial diversity was associated with reduced fecal butyric acid concentrations (r = 0.440, p = 0.024). Importantly, lower microbial diversity in the early sampling window showed a significant inverse correlation with PICU LOS (ρ = −0.428, p = 0.029), whereas fecal butyric acid alone was not directly associated with LOS (p = 0.321). In multivariable regression models adjusting for age, disease severity, and clinical exposures, microbial diversity showed a consistent inverse association with PICU LOS, although statistical significance was not reached. Conclusions: Early disruption of the gut microbiome–SCFA axis, characterized by reduced microbial diversity and lower fecal butyrate, showed trend-level associations with delayed clinical recovery in this pilot cohort. Gut microbial ecosystem integrity may serve as a biologically relevant marker of recovery trajectory beyond conventional severity scoring.
Open AccessEarly Gut Microbiome–Short-Chain Fatty Acid Axis Disruption May Be Associated with Delayed Recovery in Critically Ill Children
Background: The gut microbiome contributes to immune–metabolic homeostasis through microbial-derived metabolites such as short-chain fatty acids (SCFAs). However, whether early disruption of the gut microbiome–SCFA axis identifies impaired clinical recovery in pediatric intensive care unit (PICU) patients remains unclear. Biological markers reflecting the recovery trajectory beyond conventional severity scores remain poorly characterized in pediatric critical illness. We therefore investigated whether early microbiome disruption and fecal SCFA profiles are associated with recovery trajectory in critically ill children. Methods: In this prospective observational study (N = 26), fecal samples were collected within 5 days of PICU admission. Microbial diversity was assessed using 16S rRNA gene sequencing (Shannon index), and fecal SCFAs were quantified using targeted metabolomics. Disease severity was assessed using the Pediatric Index of Mortality 3 (PIM3). The primary outcome was PICU length of stay (LOS) as a pragmatic indicator of metabolic and functional recovery trajectory in critically ill children. Results: Younger age and higher disease severity showed a trend toward reduced microbial diversity (β = 0.066, p = 0.089, and β = −0.054, p = 0.089). Early loss of gut microbial diversity was associated with reduced fecal butyric acid concentrations (r = 0.440, p = 0.024). Importantly, lower microbial diversity in the early sampling window showed a significant inverse correlation with PICU LOS (ρ = −0.428, p = 0.029), whereas fecal butyric acid alone was not directly associated with LOS (p = 0.321). In multivariable regression models adjusting for age, disease severity, and clinical exposures, microbial diversity showed a consistent inverse association with PICU LOS, although statistical significance was not reached. Conclusions: Early disruption of the gut microbiome–SCFA axis, characterized by reduced microbial diversity and lower fecal butyrate, showed trend-level associations with delayed clinical recovery in this pilot cohort. Gut microbial ecosystem integrity may serve as a biologically relevant marker of recovery trajectory beyond conventional severity scoring.
- Open Access
- 5 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 171
Evaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.
- 5 February 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (2) , 171
Open AccessEvaluating Early Macrolide Therapy in Pediatric Campylobacter Enterocolitis: A Comparative Study
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Emergence of Macrolide-Resistant Bordetella pertussis Harboring the A2047G Mutation During the 2024 Pertussis Outbreak in Korea
Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e307. https://doi.org/10.3346/jkms.2026.41.e307
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessEmergence of Macrolide-Resistant Bordetella pertussis Harboring the A2047G Mutation During the 2024 Pertussis Outbreak in Korea
Kim Y, et al. J Korean Med Sci. 2026 Dec;41:e307. https://doi.org/10.3346/jkms.2026.41.e307
- Open Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 296-304
Surveillance of Multidrug-Resistant Organisms and Trends in Antimicrobial Susceptibility in Chronically Hospitalized Pediatric Patients
Cho YK, et al. Infect Chemother. 2025 Jun;57:e41. https://doi.org/10.3947/ic.2025.0049
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 296-304
Open AccessSurveillance of Multidrug-Resistant Organisms and Trends in Antimicrobial Susceptibility in Chronically Hospitalized Pediatric Patients
Cho YK, et al. Infect Chemother. 2025 Jun;57:e41. https://doi.org/10.3947/ic.2025.0049
- Open Access
Comparison of ELISA Versus FAMA Titers in Children After Chemotherapy and Hematopoietic Stem Cell Transplantation Who Received the Live Attenuated MAV/06 Strain Varicella Vaccine
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy. Additionally, it sought to compare fluorescent-antibody-to-membrane-antigen (FAMA) and enzyme-linked immunosorbent assay (ELISA) titers to establish effective cut-off levels for protection against varicella. Methods: The FAMA assay was conducted at the Vaccine Bio Research Institute, and a VARICELLA-ZOSTER ELISA (Vircell, Granada, Spain) kit, which relies on lysate from whole cells infected with VZV, was used to determine VZV IgG. A prospective cohort study was conducted with 76 pediatric patients under 18 years old who tested negative for VZV IgG via ELISA. Patients post-HSCT and post-chemotherapy were included. Participants received the MAV/06 varicella vaccine, and serologic responses were evaluated using ELISA and FAMA. Results: The median age of participants was 9.8 years, with acute lymphoid leukemia and acute myeloid leukemia being the most common underlying disease. Post-dose 1, the seropositive rate was 56.1% by ELISA and 97.2% by FAMA. Based on the FAMA seropositive cut-off ≥1:4, post-dose 1 geometric mean titers (GMTs) of seropositive patients in the post-HSCT group were 14.7 (95% CI, 11.3–19.1) versus 20.2 (95% CI, 13.0–31.3) in the post-chemotherapy group (p = 0.690). Based on a FAMA seropositive cut-off ≥1:16, the post-dose 1 GMT of patients considered seropositive in the post-HSCT group was 19.3 (95% CI, 15.6–24.0) versus 34.1 (95% CI, 21.0–55.4) in the post-chemotherapy group (p = 0.116), and post-dose 2 FAMA titers of 76.1 (95% CI, 14.6–398.1) in the post-HSCT group and 64.0 (95% CI, 11.4–358.1) in the post-HSCT group (p = 0.853) were observed. In patients with lower baseline FAMA titers (1:4 to 1:8), 66.7% in the post-HSCT group and 71.5% in the post-chemotherapy group achieved a greater than four-fold increase in FAMA titers post-dose 1, while those with higher baseline titers (≥1:16) did not. There were no serious adverse events or vaccine-related rashes occurring in any of the patients. Conclusion: The MAV/06 varicella vaccine is immunogenic in pediatric patients post-HSCT and post-chemotherapy, particularly when administered in a two-dose schedule using a cut-off FAMA titer of <1:16.
Open AccessComparison of ELISA Versus FAMA Titers in Children After Chemotherapy and Hematopoietic Stem Cell Transplantation Who Received the Live Attenuated MAV/06 Strain Varicella Vaccine
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy. Additionally, it sought to compare fluorescent-antibody-to-membrane-antigen (FAMA) and enzyme-linked immunosorbent assay (ELISA) titers to establish effective cut-off levels for protection against varicella. Methods: The FAMA assay was conducted at the Vaccine Bio Research Institute, and a VARICELLA-ZOSTER ELISA (Vircell, Granada, Spain) kit, which relies on lysate from whole cells infected with VZV, was used to determine VZV IgG. A prospective cohort study was conducted with 76 pediatric patients under 18 years old who tested negative for VZV IgG via ELISA. Patients post-HSCT and post-chemotherapy were included. Participants received the MAV/06 varicella vaccine, and serologic responses were evaluated using ELISA and FAMA. Results: The median age of participants was 9.8 years, with acute lymphoid leukemia and acute myeloid leukemia being the most common underlying disease. Post-dose 1, the seropositive rate was 56.1% by ELISA and 97.2% by FAMA. Based on the FAMA seropositive cut-off ≥1:4, post-dose 1 geometric mean titers (GMTs) of seropositive patients in the post-HSCT group were 14.7 (95% CI, 11.3–19.1) versus 20.2 (95% CI, 13.0–31.3) in the post-chemotherapy group (p = 0.690). Based on a FAMA seropositive cut-off ≥1:16, the post-dose 1 GMT of patients considered seropositive in the post-HSCT group was 19.3 (95% CI, 15.6–24.0) versus 34.1 (95% CI, 21.0–55.4) in the post-chemotherapy group (p = 0.116), and post-dose 2 FAMA titers of 76.1 (95% CI, 14.6–398.1) in the post-HSCT group and 64.0 (95% CI, 11.4–358.1) in the post-HSCT group (p = 0.853) were observed. In patients with lower baseline FAMA titers (1:4 to 1:8), 66.7% in the post-HSCT group and 71.5% in the post-chemotherapy group achieved a greater than four-fold increase in FAMA titers post-dose 1, while those with higher baseline titers (≥1:16) did not. There were no serious adverse events or vaccine-related rashes occurring in any of the patients. Conclusion: The MAV/06 varicella vaccine is immunogenic in pediatric patients post-HSCT and post-chemotherapy, particularly when administered in a two-dose schedule using a cut-off FAMA titer of <1:16.
- Open Access
Immunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls
Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021–2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy (n = 33), HSCT (n = 27), and healthy controls (n = 20). All participants were vaccinated with the 2021–2022 GC FLU Quadrivalent vaccine. Hemagglutination inhibition (HI) assays measured seroprotection rates (SPR), geometric mean titers (GMT), and seroconversion rates (SCR) for the four vaccine antigens (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) at one, three, and six months post-vaccination. At one month post-vaccination, all groups met the 70% SPR threshold for A/H1N1 and A/H3N2, but not for B/Victoria. For B/Yamagata, the SPR was low in the chemotherapy and HSCT groups (18.18% and 33.33%, respectively), compared to 80.00% in controls (p < 0.0001 and p = 0.0015). While A/H1N1 and A/H3N2 GMTs were protective in all groups, only controls achieved protective levels for B/Yamagata. Over time, the control group maintained >70% SPR for A/H1N1 up to six months, but the chemotherapy and HSCT groups declined by three and six months, respectively. For A/H3N2, the SPR in controls dropped below 70% at three months, while it remained above 70% in the chemotherapy and HSCT groups until three months. None of the groups achieved protective GMTs for B strains at three or six months. Pediatric patients post-HSCT or chemotherapy demonstrated a comparable immune response to healthy controls for A/H1N1 and A/H3N2, but the rapid decline in A/H1N1 antibody levels suggests the need for ongoing monitoring and adjusted vaccination schedules. The poor response to B antigens, particularly B/Yamagata, underscores the need for improved vaccination strategies in these vulnerable populations.
Open AccessImmunogenicity and Antibody Persistence of the Inactivated Quadrivalent Influenza Vaccine in Pediatric Patients Post-Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation Versus Healthy Controls
Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021–2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy (n = 33), HSCT (n = 27), and healthy controls (n = 20). All participants were vaccinated with the 2021–2022 GC FLU Quadrivalent vaccine. Hemagglutination inhibition (HI) assays measured seroprotection rates (SPR), geometric mean titers (GMT), and seroconversion rates (SCR) for the four vaccine antigens (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) at one, three, and six months post-vaccination. At one month post-vaccination, all groups met the 70% SPR threshold for A/H1N1 and A/H3N2, but not for B/Victoria. For B/Yamagata, the SPR was low in the chemotherapy and HSCT groups (18.18% and 33.33%, respectively), compared to 80.00% in controls (p < 0.0001 and p = 0.0015). While A/H1N1 and A/H3N2 GMTs were protective in all groups, only controls achieved protective levels for B/Yamagata. Over time, the control group maintained >70% SPR for A/H1N1 up to six months, but the chemotherapy and HSCT groups declined by three and six months, respectively. For A/H3N2, the SPR in controls dropped below 70% at three months, while it remained above 70% in the chemotherapy and HSCT groups until three months. None of the groups achieved protective GMTs for B strains at three or six months. Pediatric patients post-HSCT or chemotherapy demonstrated a comparable immune response to healthy controls for A/H1N1 and A/H3N2, but the rapid decline in A/H1N1 antibody levels suggests the need for ongoing monitoring and adjusted vaccination schedules. The poor response to B antigens, particularly B/Yamagata, underscores the need for improved vaccination strategies in these vulnerable populations.
- Open Access
- 1 January 2022
- Published by The Korean Society of Pediatric Infectious Diseases in Pediatric Infection & Vaccine
- Vol. 29 (3) , 161-165
A Case of Successful Treatment of Congenital Syphilis in an Extremely Preterm Baby With Severe Respiratory Distress
Cho YK, et al. Pediatr Infect Vaccine. 2022 Dec;29(3):161-165. https://doi.org/10.14776/piv.2022.29.e15
- 1 January 2022
- Published by The Korean Society of Pediatric Infectious Diseases in Pediatric Infection & Vaccine
- Vol. 29 (3) , 161-165
Open AccessA Case of Successful Treatment of Congenital Syphilis in an Extremely Preterm Baby With Severe Respiratory Distress
Cho YK, et al. Pediatr Infect Vaccine. 2022 Dec;29(3):161-165. https://doi.org/10.14776/piv.2022.29.e15